Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
06:07pm, Monday, 09'th Jun 2025
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
09:19am, Monday, 09'th Jun 2025
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Here's Why GSK (GSK) is a Strong Value Stock
10:41am, Friday, 06'th Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
12:46pm, Tuesday, 03'rd Jun 2025
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Dow Jones Industrial Average (DIA) Live June 3: OECD Cuts US GDP Forecast, DIA Dives
09:34am, Tuesday, 03'rd Jun 2025
The OECD lowered US GDP forecasts for 2025 and 2026 today. Meta and Constellation are teaming up in a nuclear power supply agreement that will last 20 years.
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
06:00am, Monday, 02'nd Jun 2025
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 202
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 30'th May 2025
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
12:23pm, Friday, 30'th May 2025
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
10:47am, Thursday, 29'th May 2025
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
Buy 5 High Dividend-Paying Giants to Stay Safe Amid Volatile Markets
08:11am, Thursday, 29'th May 2025
PM, CVS, ET, GSK and NWG, which offer high dividends and carry Zacks buy ranks, are strong picks for stability amid volatile market conditions of 2025.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
11:24am, Wednesday, 28'th May 2025
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for
GSK, Spero to stop urinary tract infection drug trial due to early success
07:18am, Wednesday, 28'th May 2025
Spero Therapeutics and partner GSK said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the t
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
12:46pm, Monday, 26'th May 2025
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
FDA Approves GSK's Nucala for Expanded Use in COPD
07:21am, Friday, 23'rd May 2025
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
